The Federal Trade Commission said Friday that it has settled a privacy investigation into drugmaker Eli Lilly's unintentional disclosure of e-mail addresses for hundreds of people.
The company does not face fines because the incident was unintentional and not a clear case of fraud, J. Howard Beales, III, director of the FTC's bureau of consumer protection, said during a press conference.
The privacy incident occurred last June when an employee accidentally sent an e-mail to 669 people with all of their e-mail addresses included in the "to:" line. The message announced the discontinuation of the company's Medi-messenger service, which allowed people taking the anti-depressant medication Prozac to create automated e-mail reminders. --Jim Hu, Special to ZDNet News